2018 International Congress » Drug-Induced Movement Disorders

1:45pm-3:15pm

A case of tardive dyskinesia and parkinsonism following use of phentermine for weight loss

R. Barmore, C. Hess, N. McFarland, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm

Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model

P. Blanchet, G. Hernandez, S. Mahmoudi, M. Cyr, J. Diaz, D. Levesque (Montreal, QC, Canada)

1:45pm-3:15pm

An oculogyric crisis after administation of alizapride: A tardive phenomenon?

A. Boogers (Edegem, Belgium)

1:45pm-3:15pm

Assessing the Effectiveness of Valbenazine in the Treatment of Tardive Dyskinesia as Determined by the AIMS and PGIC: Results from the KINECT 4 Trial

C. Singer, C. Comella, K. Farahmand, J. Burke, R. Jimenez, S. Siegert (Miami, FL, USA)

1:45pm-3:15pm

Ballism as major manifestation in Neuroleptic Malignant Syndrome in a patient toxoplasmosis cerebri

A. Wirathmawati, N. Raisa, B. Munir (Malang, Indonesia)

1:45pm-3:15pm

Clinical profile and predictors of outcome in Neuroleptic malignant syndrome and Parkinsonism hyperpyrexia syndrome

R. Kandadai, P. Dutta, S. Meka, T. Syed, S. Tandra, S. Turaga, R. Borgohain (Hyderabad, India)

1:45pm-3:15pm

Crack Dancing: An Uncommon Drug-Induced Chorea

G. Gibb, D. Nacopoulos (Erie, PA, USA)

1:45pm-3:15pm

Deep Brain Stimulation of Globus Pallidus Internus Combined with Bilateral Anterior Capsulotomy for the Treatment of Tardive Dystonia in Patients with Refractory Schizophrenia

Y. Pan, C. Zhang, Y. Zhang, L. Wang, Z. Deng, S. Zhan, J. Zhang, Y. Li, B. Sun, D. Li (Shanghai, China)

1:45pm-3:15pm

Demographic and Clinical Characteristics of Flunarizine Induced Parkinsonism: Nationwide Data Between 2000 and 2006 in Taiwan

W. Lin, CY. Wei, HJ. Chen (ChangHua, Taiwan)

1:45pm-3:15pm

Dopaminergic impairments following repeated exposure to stress on the neurotoxicity of lambda-cyhalothrin through inflammatory cytokines in rats

R. Shukla, R. Gupta, S. Goel, A. Pant, V. Khanna (Bhopal, India)

1:45pm-3:15pm

Effects of Long-Term Valbenazine on Tardive Dyskinesia by Body Region: Shift Analyses of KINECT 4 Study Results

C. Comella, C. Singer, S. Marder, J. Burke, K. Farahmand, R. Jimenez, S. Siegert (Chicago, IL, USA)

1:45pm-3:15pm

Effects of PGE inhibition on Striatal Neuroinflammation in 6-OHDA lesion

T. Adu, M. Mabandla (Durban, South Africa)

1:45pm-3:15pm

Fasciculations from a cholinesterase inhibitor

W. Deeb (Gainesville, FL, USA)

1:45pm-3:15pm

Global Improvement and Patient Satisfaction: Results from a Long-Term, Open-Label, Rollover Study of Valbenazine in Tardive Dyskinesia

S. Lessig, S. Marder, C. Verghese, J. Burke, R. Jimenez, S. Siegert, G. Liang (San Diego, CA, USA)

1:45pm-3:15pm

Hospital Utilization Rates Following Antipsychotic Dose Reductions Among Patients With Bipolar and Major Depressive Disorders

B. Carroll, F. Mu, R. Ayyagari, S. Ghandi (Frazer, PA, USA)

1:45pm-3:15pm

Interaction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesiaInteraction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesia

J.Y. Lin, Z.G. Liu, C.L. Xie, A.J. Yan (Shanghai, China)

1:45pm-3:15pm

Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease

M. Bordone, A. Damianich, A. Bernardi, E. Avale, O. Gershanik, J. Ferrario (CABA, Argentina)

1:45pm-3:15pm

Kratom withdrawal induced orobuccal dyskinesia

K. Methawasin (Nakhon Nayok, Thailand)

1:45pm-3:15pm

Levosulpiride Induced Movement Disorder: 7 cases

D. Radhakrishnan, V. Goyal (New Delhi, India)

1:45pm-3:15pm

Mild to moderate dyskinesia is not significantly related to the level of activity engagement or quality of life of patients with Parkinson’s disease

E. Goubault, S. Bogard, K. Lebel, C. Duval (Montréal, QC, Canada)

1:45pm-3:15pm

Molecular immunological action and epigenetic modification of the human papillomavirus vaccination and associated neuropsychiatric side effects

N. Kanzato, K. Nakachi, Y. Takahashi (Okinawa, Japan)

1:45pm-3:15pm

Patients experiencing peak-dose dyskinesia use re-distribution of involuntary movement amplitude throughout their body to minimize the functional impact of dyskinesia

K. Lebel, E. Goubault, S. Bogard, C. Duval (Montréal, QC, Canada)

1:45pm-3:15pm

Propofol-induced acute dystonic reaction after orthopedic surgery in a young healthy woman

R. Barbosa, M. Salavisa, M. Mendonça (Lisbon, Portugal)

1:45pm-3:15pm

Tardive Myoclonus: A Case Report

S. Gazioglu, F. Civil Arslan, V. Altunayoglu Cakmak, M. Korucuk, M. Ozmenoglu (Trabzon, Turkey)

1:45pm-3:15pm

What is the relationship between dyskinesia and performance of activities of daily living in patients with Parkinson’s disease?

E. Goubault, S. Bogard, K. Lebel, C. Duval (Montreal, QC, Canada)